Atypical Hemolytic Uremic Syndrome (aHUS) is an ultra-rare, chronic, and potentially life‑threatening condition that causes tiny blood clots to form in small vessels throughout the body. This process, called thrombotic microangiopathy, most often injures the kidneys but can involve many organs. Because aHUS can begin at any age and progress quickly, clear information and urgent evaluation are essential. This page explains the causes and risk factors for aHUS, how the disease develops, the signs and symptoms to watch for, how aHUS is diagnosed, and the full range of treatment options and support.

Atypical Hemolytic Uremic Syndrome is distinct from “typical” Shiga toxin–associated HUS. While typical HUS follows foodborne infection with Shiga toxin–producing bacteria, aHUS stems from dysregulation of the complement system, a component of innate immunity. Recognizing this difference is critical because early complement‑blocking therapy can prevent irreversible damage, reduce complications, and improve outcomes.

Atypical Hemolytic Uremic Syndrome is a disorder in which uncontrolled activation of the complement system triggers widespread injury to the lining of blood vessels. Damaged vessels promote platelet activation and fibrin deposition, leading to microvascular clots that shear red blood cells and starve organs of oxygen. The clinical hallmark is a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. aHUS is not contagious and does not spread from person to person.

Although aHUS is ultra‑rare, with an estimated incidence of about 1–2 cases per million people per year, the impact can be severe. Attacks may be sudden or evolve over days to weeks. Without timely treatment, patients can develop permanent kidney damage or multiorgan failure. Because symptoms overlap with other thrombotic microangiopathies, diagnosis requires careful testing and exclusion of other causes.

Key features of aHUS include:

• Hemolytic anemia caused by destruction of red blood cells as they traverse injured microvessels
• Thrombocytopenia due to platelet consumption in widespread microthrombi
• Acute kidney injury ranging from mild creatinine elevation to dialysis‑requiring failure

The central cause of aHUS is dysregulated activation of the complement system, particularly the alternative pathway. In many patients, inherited or de novo genetic variants impair complement regulation. In others, acquired autoantibodies disrupt normal control. Environmental or physiologic stressors can precipitate an attack in a predisposed person. Understanding risk helps guide testing, counseling, and prevention.

Common causes and risk factors include:

• Pathogenic variants in complement regulatory genes such as CFH, CFI, CFB, C3, MCP/CD46, and THBD
• Acquired anti–factor H autoantibodies that mimic loss of CFH function
• Family history of aHUS or related complement‑mediated diseases
• Infections not due to Shiga toxin–producing Escherichia coli
• Pregnancy, particularly the immediate postpartum period
• Major surgery or trauma that increases inflammatory signaling
• Solid organ transplantation and antibody‑mediated rejection
• Use of selected drugs including calcineurin inhibitors, certain chemotherapies, and immunosuppressants
• Severe or malignant hypertension that injures vascular endothelium
• Systemic autoimmune disorders such as systemic lupus erythematosus

In a healthy state, complement proteins patrol the bloodstream to fight microbes and clear damaged cells while leaving host tissues unharmed. Regulatory proteins like factor H, factor I, MCP, and thrombomodulin keep the alternative pathway in check on self surfaces. In aHUS, genetic or acquired defects weaken these brakes. The result is ongoing complement activation on endothelial cells, generation of C3 and C5 convertases, and formation of the membrane attack complex that directly injures the vessel lining.

Endothelial injury exposes procoagulant surfaces and releases von Willebrand factor, promoting platelet adhesion and aggregation. Red blood cells fragment as they pass through narrowed, fibrin‑rich microvessels, producing hemolysis and schistocytes on blood smear. The kidneys are particularly vulnerable because of their dense microvascular networks and high blood flow. Complement‑blocking therapy interrupts this cascade by preventing C5 cleavage and downstream inflammation.

Key contributors to aHUS pathogenesis include:

• Unchecked alternative pathway activation on host endothelium
• Complement‑mediated endothelial damage with increased permeability and swelling
• Platelet activation and consumption leading to thrombocytopenia
• Microvascular thrombosis that reduces organ perfusion and causes ischemic injury
• Organ‑specific vulnerability of the kidneys, brain, heart, liver, and gastrointestinal tract

Atypical Hemolytic Uremic Syndrome is categorized as an ultra‑rare disease worldwide. Incidence is estimated at roughly 1–2 cases per million per year, with prevalence influenced by survival and access to therapy. aHUS can present in infancy, childhood, or adulthood. Pediatric cases are more likely to have identifiable genetic variants, while adult cases often reflect the interaction of genetic predisposition with external triggers. There is a slight female predominance when pregnancy‑associated cases are included, and no consistent racial or geographic pattern has been established.

The natural history has changed significantly with the advent of complement inhibitors. Before targeted therapy, many patients progressed to end‑stage kidney disease or suffered recurrent, disabling relapses. Modern treatment has reduced acute mortality and improved long‑term organ preservation.

Symptoms depend on the extent and speed of microvascular injury and which organs are affected. Many patients experience a flu‑like prodrome or nonspecific malaise before the classic triad becomes apparent. Because deterioration can be rapid, early recognition and urgent medical evaluation are critical.

Common signs and symptoms include:

• Fatigue, weakness, and pallor due to hemolytic anemia
• Shortness of breath with exertion related to low hemoglobin
• Jaundice or yellowing of the skin and eyes from hemolysis
• Easy bruising, petechiae, or nosebleeds due to thrombocytopenia
• Decreased urine output or dark urine signaling kidney injury
• Swelling of the legs, ankles, or around the eyes from fluid retention
• High blood pressure that may be new or suddenly difficult to control
• Nausea, vomiting, or loss of appetite from uremia and gastrointestinal involvement
• Headache, confusion, visual changes, seizures, or altered mental status indicating central nervous system involvement
• Chest pain, irregular heartbeats, or shortness of breath suggesting cardiac involvement
• Abdominal pain or diarrhea reflecting gastrointestinal ischemia
• Low‑grade fever when inflammation or infection is present

Diagnosing aHUS requires integrating clinical features with laboratory and imaging data while excluding other causes of thrombotic microangiopathy. Because treatment is time‑sensitive, clinicians often initiate complement‑blocking therapy once key alternative diagnoses have been ruled out, even before genetic results are available. A structured approach helps avoid delay and ensures appropriate care.

Essential diagnostic steps include:

• Complete blood count to document anemia and thrombocytopenia
• Peripheral blood smear to identify schistocytes consistent with microangiopathic hemolysis
• Lactate dehydrogenase elevation and low haptoglobin supporting active hemolysis
• Serum creatinine and blood urea nitrogen to assess kidney function
• Urinalysis for hematuria and proteinuria indicating glomerular injury
• Complement levels such as C3 and C4 that may be reduced in aHUS
• ADAMTS13 activity testing to exclude thrombotic thrombocytopenic purpura
• Stool testing for Shiga toxin when infection is suspected to exclude typical HUS
• Genetic testing for variants in CFH, CFI, CFB, C3, MCP/CD46, and THBD
• Anti–factor H antibody testing when acquired dysregulation is suspected
• Renal ultrasound to assess kidney size and echogenicity
• Brain imaging with CT or MRI when neurological symptoms occur
• Kidney biopsy in selected cases to confirm thrombotic microangiopathy and gauge severity

Differential diagnosis for Atypical Hemolytic Uremic Syndrome (aHUS)

Several disorders share features with aHUS and must be methodically considered. Distinguishing these conditions guides urgent treatment choices and impacts outcomes. Clinical context, ADAMTS13 testing, infection studies, coagulation panels, and imaging all contribute to accurate differentiation.

Common conditions in the differential include:

• Shiga toxin–producing Escherichia coli HUS following diarrheal illness
• Thrombotic thrombocytopenic purpura driven by severe ADAMTS13 deficiency
• Malignant hypertension with vascular endothelial injury
• Systemic lupus erythematosus with secondary thrombotic microangiopathy
• Disseminated intravascular coagulation associated with sepsis or malignancy
• Drug‑induced thrombotic microangiopathy from calcineurin inhibitors or chemotherapies
• Antiphospholipid syndrome with microvascular thrombosis

The treatment of aHUS focuses on rapid complement blockade, aggressive supportive care, and prevention of relapse. Timely therapy can reverse organ injury and dramatically improve prognosis. Care is often coordinated by nephrology, hematology, and critical care teams with input from genetics and infectious diseases.

Core treatment approaches include:

• Eculizumab, a monoclonal antibody that inhibits C5, halting terminal complement activation and preventing membrane attack complex formation
• Ravulizumab, a longer‑acting C5 inhibitor that allows less frequent dosing while providing comparable efficacy to eculizumab
• Vaccination against Neisseria meningitidis and other encapsulated bacteria prior to or promptly after starting C5 inhibition, with antibiotic prophylaxis when indicated
• Dialysis for severe acute kidney injury when metabolic control or volume management is required
• Packed red blood cell transfusion to treat symptomatic anemia
• Platelet transfusion in selected bleeding scenarios after specialist consultation
• Antihypertensive therapy to control blood pressure and reduce further endothelial injury
• Nutritional, fluid, and electrolyte management tailored to kidney function and catabolic state
• Therapeutic plasma exchange when complement inhibitors are unavailable, when anti–factor H antibodies are suspected, or as a temporizing measure during diagnostic clarification
• Careful review and discontinuation of potential trigger medications such as calcineurin inhibitors when feasible
• Multidisciplinary counseling regarding genetic findings, recurrence risk, and implications for family members

Even with treatment, aHUS can lead to significant short‑ and long‑term complications. Awareness of these risks supports close monitoring, early intervention, and patient education. Many complications are preventable or mitigated through consistent follow‑up and adherence to therapy.

Potential complications include:

• Permanent loss of kidney function leading to chronic kidney disease or end‑stage kidney disease
• Recurrent aHUS flares during infections, pregnancy, or surgery
• Resistant or malignant hypertension with cardiovascular sequelae
• Neurological injury including stroke, seizures, and cognitive changes
• Cardiac involvement such as heart failure or arrhythmias
• Hepatic or pancreatic inflammation with abnormal laboratory tests
• Increased infection risk associated with C5 inhibition, particularly meningococcal disease
• Treatment‑related adverse effects including infusion reactions and headaches

The prognosis for aHUS has improved substantially with modern complement‑blocking therapy. Many patients recover kidney function and avoid dialysis when treatment is started early. Long‑term outcomes depend on the speed of diagnosis, severity of the initial episode, genetic background, and adherence to therapy. Because relapses can occur, ongoing surveillance and rapid access to care are essential.

Important considerations for prognosis include:

• Earlier initiation of C5 inhibition is linked to better renal recovery and fewer chronic complications
• Genetic variants in CFH or combined defects may predict higher relapse risk and more severe disease
• Pregnancy‑associated aHUS generally responds to complement blockade but requires careful planning and close monitoring in future pregnancies
• Patients who experience delayed treatment or repeated flares are more likely to develop chronic kidney disease
• With sustained therapy and monitoring, many individuals can return to normal activities and maintain good quality of life

While aHUS cannot be completely prevented, risk can be reduced by managing triggers, planning for high‑risk situations, and maintaining preventive care. Education empowers patients and families to recognize early warning signs and seek care quickly. Genetic counseling helps clarify inheritance patterns and inform reproductive decisions.

Practical prevention strategies include:

• Genetic counseling and testing for patients and at‑risk relatives when indicated
• Preconception and prenatal planning for individuals with aHUS history or complement variants
• Vaccinations per guidelines, including meningococcal vaccines before or soon after starting C5 inhibitors
• Prompt evaluation and treatment of infections to minimize inflammatory triggers
• Medication review to avoid or limit drugs associated with thrombotic microangiopathy when alternatives exist
• Blood pressure monitoring and control to protect vascular health and kidney function
• Scheduled follow‑up with nephrology and hematology teams to adjust therapy and detect relapse early

Living with aHUS involves medical care, self‑management, and emotional support. Many patients lead active lives when treatment is optimized and complications are prevented. A personalized care plan should address daily health, work or school needs, family planning, and mental well‑being. Support groups and patient organizations can provide connection and practical guidance.

Helpful tips for day‑to‑day living include:

• Keeping a written treatment plan that lists medications, vaccine status, and emergency contacts
• Learning early warning signs of relapse such as unusual bruising, decreased urine, headaches, or new fatigue
• Staying current with vaccines and discussing antibiotic prophylaxis when appropriate
• Coordinating care among specialists and ensuring all providers know you receive complement inhibitors
• Following kidney‑friendly nutrition advice and fluid goals as guided by your care team
• Maintaining physical activity as tolerated to support cardiovascular and mental health
• Seeking counseling or peer support to manage stress, anxiety, or uncertainty
• Planning travel with infusion schedules and carrying a medical alert identifying aHUS and current therapy

Atypical Hemolytic Uremic Syndrome is a rare but serious complement‑mediated disease that can rapidly injure the kidneys and other organs. It is distinct from typical, infection‑related HUS and requires specialized, time‑sensitive care. Recognizing the symptoms, ruling out look‑alike conditions, and starting complement‑blocking therapy quickly are central to improving outcomes. With eculizumab or ravulizumab, many patients recover organ function, reduce relapse risk, and live full, active lives. Ongoing follow‑up, vaccination, and patient education remain essential parts of long‑term management.

If you or a loved one is facing aHUS, know that advances in diagnosis and treatment have transformed this condition. Working closely with your healthcare team and connecting with support resources can help you navigate decisions, prevent complications, and maintain quality of life.

1. Raina R, Krishnappa V, Blaha T, Kann T, Hein W, Burke L, Bagga A. Atypical hemolytic‑uremic syndrome: An update on pathophysiology, diagnosis, and treatment. Ther Apher Dial. 2019;23(1):4–21.
2. Loirat C, Frémeaux‑Bacchi V. Atypical hemolytic‑uremic syndrome. Orphanet J Rare Dis. 2011;6:60.
3. Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: What is it, how is it diagnosed, and how is it treated? ASH Educ Program Book. 2012;2012(1):473–481.
4. Zuber J, Le Quintrec M, et al. Clinical presentation and management of atypical hemolytic uremic syndrome. Ther Apher Dial. 2024;28(2):145–156.